Skip navigation
Merrion pharmaceuticals - making medicines better
Skip navigation

Press Releases / Publications

Download Adobe Acrobat Reader Some of the articles are in PDF format. You will need Adobe Acrobat Reader to view them. Click on the logo to download it for free.

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006/04


December Novo Nordisk starts phase 1 trial with oral insulin analogue - Merrion Pharmaceuticals earns USD 2 million milestone payment
November Merrion Pharmaceuticals to Present GIRES data at the 2009 Annual AAPS Meeting & Exhibition, Los Angeles, California
October Merrion Pharmaceuticals Video Overview & Interview with John Lynch, CEO
October Merrion Strives to turn IV drugs into tablets, Genetic Engineering & Biotechnology News, Oct 2009.
October Merrion Pharmaceuticals Plc Announce the Official Opening of their New State of the Art Facility in Citywest.
October Merrion Pharmaceuticals Plc to Present at AACR-NCI-EORTC International Molecular Targets & Cancer Therapeutics Conference in Boston, MA
October Merrion Pharmaceuticals Plc Announce Presentation at ASCO, 2009 Breast Cancer Symposium, San Francisco, 9th Oct 2009
September Jonathan O‘Connell, CFO, Presentation at UBS Global Life Science Conference, New York, Mon 21st Sept 2009
September Merrion Pharmaceuticals Outlook - Edison Investment Research, September 2009
September Merrion Pharmaceuticals plc announces commencement of Second feasibility collaboration programme with the Swiss based Ferring Pharmaceuticals SA
July Impact of Film Properties and Drug Physicochemical Properties on Diffusion through a Poly (Vinyl Alcohol) Film for the Development of GIRES™
Presented at the 36th Annual Controlled Release Society Meeting, July 2009, Copenhagen, Denmark.
June A spoonful of GIPET: How Merrion Pharmaceuticals turns blockbuster IV Drugs into Pills
Christin Melton, Oncology & Biotech News, June 2009
June Zoledronic acid for treament of prostate cancer
Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals, eCancer Medical Science
Ecancer TV -
June Oncology Business Review
June Merrion Drug Orazol could be used to treat Breast Cancer - The Irish Times, 01 June 2009
May Positive Trials for Oral Cancer Treatment - Sunday Business Post, 31 May 2009
May Merrion Cancer Tablet Success - The Sunday Times, 31 May 2009
May Orazol Final Phase II Study Results - Presented at ASCO, American Society of Clinical Oncology Annual Meeting, 31st May 2009, Orlando, Florida
May Merrion Pharmaceuticals Plc Announces positive Final results on key Phase II Orazol™ study
May Merrion Pharmaceuticals Plc Announces Preliminary results on Phase II Orazol™ study
May A View from the Top - Merrion Pharmaceuticals CEO talks about running a small Irish Company that is excelling on the world stage
April Merrion Pharmaceuticals Announces that the American Society of Clinical Oncology (ASCO) has accepted an abstract from Merrion‘s Phase IIB clinical trial on Orazol™
March Merrion Pharmaceuticals Plc Announces Preliminary Results for the year ended 31 December 2008
March Merrion Pharmaceuticals Announces Commencement of Dosing of Orazol™ in US Clinical Study
February Merrion CEO, John Lynch, Addresses Biobusiness Conference, Geneva, Switzerland.
February Merrion Pharmaceuticals Plc Announces Board Changes
February Merrion completes patient enrolment in Phase IIb study - Results will be announced in Q2 2009
February Merrion Pharmaceuticals Retains Sage Group to Augment Strategic Alliance Efforts
January Merrion Announces License Deal with Novo Nordisk - Financial Times, 27th Jan 2009
January Merrion in Deal with World‘s Largest Insulin Maker - Irish Times, 17th Jan 2009
January Merrion bottles up $58m diabetes pill deal - Irish Independent, 17th Jan 2009
January World‘s Largest Insulin Maker takes 1m Stake in Irish Drug Company - Irish Examiner, 17th Jan 2009
January "Moving up the value chain" - Interview & Feature, Business & Finance Magazine, January 2009
January Tanaiste Welcomes second Merrion Pharmaceuticals Contract with Novo Nordisk
January Merrion Announces Second License Agreement with Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) - Novo Nordisk makes equity investment in Merrion